Evidence map›Paper›PMID 35256958›Full record

ArticleActa pharmaceutica Sinica. B2022

Perfluorooctyl bromide nanoemulsions holding MnO

Xinping Kuai, Yuefei Zhu, Zheng Yuan, Shengyu Wang, Lin Lin, Xiaodan Ye, Yiping Lu, Yu Luo, Zhiqing Pang, Daoying Geng and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. UltrasensitiveAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Xinping KuaiDepartment of Radiology, Huashan Hospital, Fudan University, Shanghai 200040, China.
Yuefei ZhuSchool of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai 201203, China.
Zheng YuanDepartment of Radiology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai 201204, China.
Shengyu WangDepartment of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201800, China.
Lin LinDepartment of Radiology, Huashan Hospital, Fudan University, Shanghai 200040, China.
Xiaodan YeDepartment of Radiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China.
Yiping LuDepartment of Radiology, Huashan Hospital, Fudan University, Shanghai 200040, China.
Yu LuoState Key Laboratory of High Performance Ceramics and Superfine Microstructure, School of Chemical Science and Engineering, Shanghai 200092, China.
Zhiqing PangSchool of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai 201203, China.
Daoying GengDepartment of Radiology, Huashan Hospital, Fudan University, Shanghai 200040, China.
Bo YinDepartment of Radiology, Huashan Hospital, Fudan University, Shanghai 200040, China.
Fudan University · CNShanghai Jiao Tong University · CNShanghai First Maternity and Infant Hospital · CNState Key Laboratory of High Performance Ceramics and Superfine Microstructure

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor-targeted immunotherapy is a remarkable breakthrough, offering the inimitable advantage of specific tumoricidal effects with reduced immune-associated cytotoxicity. However, existing platforms suffer from low efficacy, inability to induce strong immunogenic cell death (ICD), and restrained capacity of transforming immune-deserted tumors into immune-cultivated ones. Here, an innovative platform, perfluorooctyl bromide (PFOB) nanoemulsions holding MnO

Indexed as

Dual-modality imagingGlutathione depletionHigh-intensity focused ultrasoundImmunogenic cell deathManganese dioxide nanoparticlesNanoemulsionsTumor microenvironment

Identifiers

PMID35256958
PMCPMC8897201
OpenAlexW3192379540

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.